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doxorubicin in Chinese hamster ovary cells
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Summary We have isolated from Chinese hamster ovary cells, 30 sublines resistant to vincristine, doxorubicin
or etoposide and 43 sublines evading treatment with a pair of these drugs. Isolated in one step and under low
selective pressure. subhnes were 3- to 25-fold more resistant to their selecting drug(s) than the parental cells.
Possible P-glycoprotein-associated multidrug resistance was investigated through pgp gene copy number and
mRNA expression level. DNA topoisomerase II alteration was evaluated from the ability of nuclear extracts
to form cleavable complexes. Vincristine (all sublines) and doxorubicin (6 7 sublines) preferentially selected for
pgp gene amplification and mRNA overexpression, whereas selection with etoposide resulted in a decrease of
cleavable complex formation in 11 out of 13 sublines. A common pgp gene-mediated resistance was found in
the 13 doxorubicin plus vincristine-selected sublines, whereas all but one of the 12 etoposide plus vincristine-
resistant sublines displayed both pgp mRNA overexpression and decreased ability to form cleavable com-
plexes. Among the 18 doxorubicin plus etoposide selected sublines, five exhibited a decreased ability to form
cleavable complexes only, six exhibited pgp mRNA overexpression only and six exhibited both alterations.
Overall, drug resistance could not be attributed to either mechanism in three of the 73 sublines. We conclude
that under low selective pressure it is possible to find a combination of drugs which require simultaneous
selection of more than one resistance mechanism; such cells emerge with very low frequency.
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Drug resistance is, beside the poor selectivity of antitumoral
agents, the main limitation of cancer chemotherapy (Goldie
and Coldman, 1984). Regimens usually involve at least two
drugs, but resistance often develops simultaneously to several
agents. Typically, the frequency of resistance to combined
drugs is much higher than the product of the monoresistant
frequencies (Giulotto et al., 1987; Rice et al., 1987; Soues and
Charcosset, 1993). Multiple immunities may result from a
specific phenotype, characterised by DNA amplification. For
instance, the high frequency of simultaneous resistance to
methotrexate and N-phosphonacetyl-L-aspartate is due to
gene amplification of both target enzymes: dihydrofolate-
reductase and polypeptide having carbamyl phosphate syn-
thetase, aspartate transcarbamylase and dihydroorotase
activities (CAD) (Giulotto et al., 1987). Similarly, concurrent
treatment with methotrexate and doxorubicin (DOX) induces
amplification of the dihydrofolate reductase and of the mul-
tidrug resistance-associated genes (Rice et al., 1987). Multiple
drug resistance (MDR) may also follow overexpression of the
multidrug efflux pump P-glycoproteins (PGP), coded by three
classes of genes (Georges et al., 1990; Gottesman and Pastan,
1993). Transfection of hamster pgpl (class I genes) and of
mouse mdrl gene, homologous to the hamster pgp2 gene
(class II genes), has been shown to induce the classical MDR
phenotype (Gottesman and Pastan, 1993; Devine and Melera,
1994). Modification of DNA topoisomerase II, or a nuclear
decrease in this enzyme, may also confer resistance to several
of its poisons (Charcosset et al., 1988; Fernandes et al., 1990;
Schneider et al., 1990; Harker et al., 1991; Hinds et al., 1991;
Rappa et al., 1992), the phenotype being referred to as
atypical MDR (at MDR) (Danks et al., 1988).
Etoposide (ETO) is an epipodophyllotoxin derivative
which selects cells with quantitative and/or qualitative altera-
tions of DNA topoisomerase II (Ferguson et al., 1988; Long
et al., 1991; Takano et al., 1991; Webb et al., 1991; Danks et
al., 1993; Patel and Fisher, 1993; Sullivan et al., 1993; Ritke
et al., 1994). To date, only one cell line exhibited mdrl
mRNA overexpression, without topoisomerase II modifica-
tion, after selection by teniposide (Long et al., 1991). Vincris-
tine (VCR) is a vinca alkaloid which selects for modified
tubulin, its target (Houghton et al., 1985; Pain et al., 1988),
or for PGP overexpression (Georges et al., 1990). Finally,
DOX is a DNA intercalative drug, which selects for DNA
topoisomerase II modification (De Jong et al., 1990; McPher-
son et al., 1993) as well as for the MDR phenotype (Georges
et al., 1990; Slapak et al., 1990).
In previous studies, we reported that the frequencies of
resistance to combinations of DOX, VCR and ETO suggest
that both common and independent mechanisms ofresistance
can be selected in Chinese hamster ovary (CHO) cells (Soues
and Charcosset, 1993). In this paper, we document that VCR
and DOX preferentially select CHO cells with amplification
and overexpression of the pgp genes, whereas DNA
topoisomerase II alteration almost systematically accounts
for ETO resistance. We also provide evidence that amp-
lification of the pgp genes develops without DNA topoiso-
merase II modification after treatment with VCR plus DOX,
whereas both pgp gene amplification and DNA topoiso-
merase II alteration occur in VCR plus ETO-selected sub-
lines. When the selection is achieved with a combination of
DOX plus ETO, drug resistance is ensured by either or both
mechanisms. We conclude that cells selected with two drugs
tend to exhibit a mechanism that allows them to resist both
drugs simultaneously. Alternatively cells need two, indepen-
dent, mechanisms of resistance.
Materials and methods
Cell lines and cell culture
The Chinese hamster ovary (CHO) cells AA8 (Thompson et
al., 1980) were used as parental cell line and grown as
previously described (Muller et al., 1992). Chinese hamster
ovary cell line AuxBl and its colchicine-resistant subline
CHRC5 (Kartner et al., 1985) were kindly provided by Dr
RM Baker (RPMI, Buffalo, NY, USA).
Drugs
Aqueous solution of VCR (Oncovin) was purchased from
Lilly France (Saint Cloud, France). DOX (Adriblastine) was
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purchased from Laboratoire Roger Bellon (Neuilly-sur-Seine,
France) and stored at -20-C after dissolution in water at
1 mgml-'. ETO was kindly provided by Drs HM Holava
and JD Matiskella (Bristol Myers, Wallingford, CT, USA) or
by Dr C Dubray (Laboratoires Sandoz, Rueil-Malmaison,
France), and 10 mM aliquots in dimethylsulphoxide were
stored at -20 C.
Selection ofresistant cells anddose-ependent survivalanalysis
Selection of AA8 cells (105 to 106 cells in 100mm Petri
dishes) was achieved in 13-15 days in the continuous
presence of the selecting drug concentration. Care was taken
to avoid cell-to-cell contact for possible metabolic coopera-
tion (Hooper and Subak-Sharpe, 1981). Colonies of various
morphologies were isolated, and expanded in the presence of
the seecting drug(s) for up to 2 months, before constitution
offrozen stocks. Each selected sublie is defined according to
its parental cells (AA8), followed by the seecting drug(s)
used (DOX, VCR and/or ETO) and a clone number (i.e.
AA8/DOX + VCRB6 stands for clone B6 sekcted from AA8
cells by DOX plus VCR).
Drug cytotoxicity was determined by colony formation
assay after 6-8 days of continuous exposure to the drug, as
previously (Muler et al., 1992). No inoculum effect was
observed with either parental or seled cells (Ohnuma et al.,
1986). Each cell lne was characterised by the concentration
of drug resulting in 10% survival (D1O) and by its resistance
index (RI), defined as the ratio of the D0 value for a
particular subline over that for the parental cell line.
Northern and Southern blots
RNA and DNA were extracted by the guanidine thiocyanate
method, separated using a caesium chloride cushion (Chirg-
win et al., 1979; Muller et al., 1992) and purified by
phenol-chloroform extraction. Four micrograms of total
RNA was resolved in 1.2% agarose gel conning 2.2M
formaldehyde, and Northern blots were performed as des-
cribed by Dautry et al. (1988). The amount of rRNA loaded
was quantified by ethidium bromide staining (Muller et al.,
1992), and that of actin mRNA was probed, using a trans-
cript of pBACT 5 plasmid containing the 600bp TagI/PstI
fragment of the mouse gene (Dautry et al., 1988), after
labelling with [2P]UTP. A 1.2 kb cDNA fragment encompas-
sing from nucleotide 3051 to the poly-A tail of the human
mdrl gene (kindly provided by Dr T Tsuruo, Tokyo, Japan)
was labelled with [-_32P`JdCTP, and used to probe the pgp hamste mRNA. The amount ofpgp mRNA in each cell line
was quantified by densitometry of the autoradiograms, using
a double-beam microdensitometer (MKIIIC, Joyce, LoebL
UK), and averaged from a minimum of two RNA extrac-
tions. Ten micrograms of total cellular DNA was developed
in 0.8% agarose gel after complete digestion by EcoRI.
Southern blots were probed using the 1.2 kb human mdfrl
cDNA insert, which hybridised to eight EcoRI fragments,
covering the three pgp genes (Riordan et al., 1985; Ng et al.,
1989; MuLer et al., 1992). DNA and RNA from CHO
CHRC5 and AuxBl cells were extracted, and analysed as
positive and negative controls respectively.
Preparation ofthe nuclear extracts andDNA topoisomerase II
assay
Nuclear extracts were prepared according to Gisson et al.
(1986) with minor modifications as described by Charcosset
et al. (1988). Briefly, 4-6 x 107 exponentially growing cells
were trypsinised, washed with phosphate-buffered saline, and
the nuclei were extraed at 4-C by Dounce homogenisation in a swelling buffer containing 0.3% Triton X-100 (v/v). Nuclei were further purified by centrifugation through a
sucrose cushion, and the concentration of sodium chloride
was raised to 0.35 M to extract DNA topoisomerase H. For
the purpose of comparison, AA8 cells were processed systematically with resistant sublines. In preliminary experi-
ments we determined that the protein content in nuclear
extracts was directly proportional to the initial number of
cels used for the extraction. Therefore, the total protein concentration was used to normalise the nuclear extracts.
Etoposide-stimulated DNA cleavage activity was assayed
using the ability of the 0.35 M sodium chloride nuclear
extract to linearise supercoiled pBR 322DNA, as descrbed by Charcosset et at. (1988). Samples were analysed by gel electrophoresis in 0.8% agarose gel in the presence of
ethidium bromide and pictures were taken under UV light. The percentage ofform Ill plasmid (linear) was estimated by scanning negative films. With all sublines, the DNA cleavage activity of the nuclear extracts increased with the concentra-
tion of ETO added and plateaued for concentrations higher than 64gM. The percentages ofcleavable complexes reported in this study correspond to that measured for a given subline, relative to that for the parental cell line, in the presence of a
saturating concentration of ETO (128 gM).
Resuls
Selection ofAA8 colonies resistant to DOX, VCR and/or ETO
We have isolated from CHO-AA8 cells, under low selective
pressure and in a single step, 30 sublines resstant to either
DOX, VCR or ETO, and 43 sublines resistant to combina-
tions of these drugs. D1O values for DOX, VCR and EFO of
the AA8 cells were 59 ± 2.6 nM, 23 ± 4.5 nM and 630 ± 70
nM respectively (mean ± s.d. of4-10 determinations, each in
triplicte). Selecting concentrations, frequency of surviving
cells, number ofcolonies obtained and plating efficencies are
summarised in Table I. To select single drug-resistant col-
onies, we used 3 x D1O, which induced a frequency ofsurviv-
ing cells of about 10-5 to 10-4. To obtain doubly resistant
colonies, we combined 0.28 pM DOX with 0.05#AM VCR or
1.6FLM ETO (or VCR and ETO at the same concentrations).
These combinations induced a frequency ofsurviving cells of
10-7 to 10-6. The frequency of surviving cells was 700-fold
greater than the product of each single drug resistance fre-
quency with the association DOX plus VCR, approximately
equal to this product with VCR and ETO, and intermediate
with DOX plus ETO (Soues and Charcosset, 1993).
The plating efficiency of each subline was determined in
the absence as well as in the presence, of the selecting drug (Table 1). Without drug, plating efficiecies were in the range
TaeI SensitivityofAA8cells toDOX, VCRorETO,seectiveconditionsandplatingeffidenciesofsublinesresistant toDOX,
VCR or ETO or to a combination ofthese drugs
Selecting conenats ( w) Selecting Nw'ber of Piriingefficiency (%)° Subline DOX VCR ETO freqwuecy colonies Nodrug DOX VCR ETO
AA8/DOX 0.18 - - 5 x 10-5 7 42-57b 30-46 - - AA8/VCR - 0.07 - 2 x 10-5 10 67-89 - 44-66 - AA8/ETO - - 2.00 2x 10-4 13 44-88 - - 34-51
AA8/DOX + VCR 0.28 0.05 - 2 x 10-7 13 48-88 30-75 25-60 - AA8/VCR + ETO - 0.05 1.60 2 x 10-' 12 38-82 - 32-72 30-73 AA8/DOX + ETO 0.28 - 1.60 8 x 10-7 18 40-70 25c-61 - 26-63
'Patingefficiency wasdetermined bycolony-formingassay, undercontinuousexpoe tothedrug.bRange: eachvalue isthe mean of2-5 determinations (each in tipliate). cIhe plating f ies of2 ofthe 18 sublines were 4% and 6%.Do" drug rsnc
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of 40-90%. In the presence of the selecting drug, cells
retained 51-91% of this plating efficiency. Thus most sub-
lines effectively resisted their selecting drug (Thompson and
Baker, 1973). However, sublines exhibited relatively low level
of resistance to the selecting drug: RI values extended from
3- to 25-fold (Figures 1-6). In an attempt to identify possible
PGP overexpression and/or topoisomerase II alteration, we
characterised these sublines for pgp gene copy number, pgp
mRNA overexpression and the ability of the nuclear extracts
to form cleavable complexes in the presence of ETO.
Characterisation ofthe DOX-resistant sublines
Among the DOX-selected sublines, six out of seven exhibited
pgp gene amplification as well as pgp mRNA overexpression,
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whereas formation ofcleavable complexes was similar to that
of the parental cells (Figure 1). Amplification of the pgp
genes appeared homogeneous in sublines AA8/DOX.A1, A3,
A4 and A5 (i.e. the relative intensities of the EcoRI DNA
fragments were similar to that of the AA8 cells). In contrast,
in sublines AA8/DOX.A6 and B6, the most amplified EcoRI
fragments were those corresponding to the pgp2 gene,
whereas the bands ofpgp3 gene were the least amplified. The
level of mRNA overexpression was not related to the gene
amplification pattern or level. For instance, sublines AA8/
DOX.A1 and A6 had the highest level of mRNA detectable,
but different pgp gene amplification pattern and level. In
addition, there was no correlation between the sensitivity to
DOX and the level of pgp gene amplification or mRNA
overexpression: RI values were between 5 and 10 with all
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Fgwe 1 Characterisation of the DOX-resistant sublines. Top: resistance indexes to DOX of the selected sublines. Middle:
Southern blot analysis. The amount of DNA loaded on the gel was 10pg for the CHO cells and 3 Lg for the CH1C5 cells (used as
positive control). The EcoRI fragments which hybridise to the human mdl probe are each attributed to one of the hamster pgp
genes, according to their size in kilobases. Sublines A6 and B6 presented a preferred pgp2 amplification pattern. In the other
sublines, the relative intensity of each band was similar to that of the AA8 parental cells. The lower panel indicates the fold
increase in the pgp mRNA expression level (relative to the average obtained with the AA8 cells). There was no pgp gene
amplification in subline A2, which was the only one to exhibit a decreased ability to form cleavable complexes (not shown).
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F*gwe 2 Characterisation of the VCR-resistant sublines. Top: resistance indexes to VCR. Middle: Southern blot analysis. Bottom:
fold increase in pgp mRNA level (as in Figure 1). All sublines exhibited both pgp gene amplification and mRNA overexpression.
Sublines B16, C13 and C14 exhibited a homogeneous pgp gene amplification pattern, the other sublines a specific pgpl
amplification. As expected with VCR-slected cels, no decrease in the ability to form cleavable complexes was detected (not shown).
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sublines (Figure 1). In the seventh subline (AA8/DOX.A2),
neither pgp gene amplification nor mRNA overexpression
was detected, but in vitro drug-dependent DNA cleavage was
only 50% that of the AA8 cells, suggesting a decrease in the
ability to stabilise cleavable complexes. Topoisomerase H
alteration, and pgp gene amplification can both confer cross-
resistance to several drugs. Therefore we examined the resis-
tance of four sublines to VCR and ETO. Sublines AA8/
DOX.A4, A5 and A6, with pgp gene amplification, presented
a cross-resistance to VCR and ETO (RI values were between
4 and 6, Table II). Subline AA8/DOX.A2, with a reduced
ability to form cleavable complexes, retained sensitivity to
VCR (RI value of 0.9), but was 3-fold cross-resistant to
ETO.
Thus, DOX preferentially selects AA8 cells with pgp gene
amplification, resulting in VCR and ETO cross-resistance.
Modification of topoisomerase II (without pgp gene amplifi-
cation) accounted for DOX resistance and ETO cross-
resistance in one subline only.
Characterisation ofthe VCR-resistant sublines
Compared with the parental cells, pgp genes were amplified
in all VCR-selected sublines, whereas pgp mRNA was
x AA8/ETO
e 15 -2tg3!SEE
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Figure 3 Characterisation of the ETO-resistant sublines. Top:
resistance indexces to ETO. Bottom: ability to form cleavable
complexes (expressed as a percentage of that determined for the
AA8 parental cells); n (for normal) indicates that no difference
with the AA8 parental cells could be detected. All but two
sublines (B4 and C3) had a reduced ability to form cleavable
complexces. There was no detectable pgp gene amplification with
any of the sublines (the amount of each pgp gene was similar to
that of the parental cells), but subline C6 exhibited a slight
increase in mRNA level (not shown).
moderately overexpressed (Figure 2). In sublines AA8/
VCR.B16, C13 and C14, the relative intensities of the DNA
fragments were similar to that of the parental cells, but in
sublines AA8/VCR.A12, BlI, B12, B14, C12 and C16, pgpl
gene was preferentially amplified. The pgpl gene was partic-
ularly amplified in subline AA8/VCR.All, but the intensity
of the 4.2 kb fragment ofpgp2 gene was also increased. Here
the RI values were related to the level ofpgpl amplification.
Sublines with preferential pgpl gene amplification had RI
values higher than 11, and when there was homogeneous
amplification the RI was still higher for sublines with high
pgpl copy number. In fact, subline AA8/VCR.C14, with the
lowest pgpl amplification, had the lowest RI value (4.8).
Three sublines with representative amplification pattern
(AA8/VCR.B14, B16 and C13) exhibited cross-resistance to
both DOX and ETO (RI values higher than 5.3, Table II),
whereas subline AA8/VCR.C14 was both DOX and ETO
sensitive (RI values of 1.1 and 1.5 respectively). It is unlikely
that topoisomerase II modification had been co-selected with
pgp amplification. Indeed, the capacity to form cleavable
complexes was similar to that of the AA8 parental cells in
sublines AA8/VCR.B14, B16, C12, C13 and C14.
Taken together, these data suggest that VCR typically
selects AA8 cells with amplification and overexpression of
pgp genes resulting in cross-resistance to DOX and ETO.
Characterisation ofthe ETO-resistant sublines
A decreased ability to form cleavable complexes was
observed in 11 out of the 13 ETO-resistant sublines, whereas
none exhibited pgp gene amplification (Figure 3). The percen-
tages of drug-stimulated DNA cleavage were 2- to 20-fold
lower than that of the parental cells, and RI values varied
between 3.5 and 19. Among these sublines, AA8/ETO.C6,
with a high RI value (11.9), exhibited a slight pgp mRNA
overexpression. Sublines AA8/ETO.B4 and C3 are poten-
tially interesting, because neither pgp gene amplification,
mRNA overexpression nor decreased cleavable complex for-
mation could explain their high RI values (10.8 and 18.9
respectively). ETO and DOX are both topoisomerase II
poisons, and VCR, while a tubulin binder, preferentially
selects PGP-associated multidrug resistance. Possible cross-
resistance to DOX or VCR of sublines AA8/ETO.A5, Bl
and B2 was tested. Cross-resistance to DOX was only about
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Figure 4 Charactenrsation of the DOX plus VCR-resistant sublines. Top: resistance indexes to DOX ( _ ) and to VCR x ).
Middle: Southern blot analysis. Bottom: fold increase in pgp mRNA level (as in Figure 1). All sublines exhibited a homogeneous
pgp gene amplification pattern, except subline B3, which presents a preferred pgp2 amplification pattern. All sublines overexpressed
to vanous extents the pgp mRNA. No alteration of the ability to form cleavable complexes was detected (not shown).
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2-fold, and cells retained sensitivity to VCR (RI values were Characterisation ofthe DOXplus VCR-resistant sublines
between 0.9 and 1.2; Table IT).
Therefore, ETO preferentially selects AA8 cells through All the sublines selected with a combination of DOX and
topoisomerase II modification. Yet, the highest RI values VCR exhibited pgp gene amplification and pgp mRNA
were obtained with a concomitant pgp gene overexpression in overexpression, but, in contrast to the VCR-selected cells,
one subline, and through neither mechanism in two sublines. there was no evidence of specific pgpl amplification (Figure
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Fugwe 5 Charactensation of the ETO plus VCR-resistant sublines. Top: resistance indexes to ETO (LII) and to VCR ().
Middle: Southern blot analysis. Bottom: fold increase in pgp mRNA level (as in Figure 1) and ability to form cleavable complexes
(as in Figure 3). Seven sublines exhibited a homogeneous pgp gene amplification pattern (A3, B2, B3, C3, C6, F2 and G2), the
other sublines (A6, BI, B4, E3 and F3) a preferred pgp2 amplification pattern. All sublines overexpressed to various extents the pgp
mRNA, and all but subline E3 had a reduced ability to form cleavable complexes.
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Figre 6 Characterisation of the DOX plus ETO-resistant sublines. Top: resistance indexes to DOX ( ) and to ETO (LO ).
Middle: Southern blot analysis and Northern blot analysis [total RNA (4gLg) was hybridised to the human mdrl probe; the arrows
indicate the position of 28S rRNA]. Bottom: fold increase in pgp mRNA level (as in Figure 1) and ability to form cleavable
complexes (as in Figure 3). Sublines A5, C3, D5, E4, G5 and H6 exhibited pgp mRNA overexpression only, sublines A3, C5, D2,
GI and G4 exhibited a decreased ability to form cleavable complexes only and sublines A2, A4, Bl, B4, C6 and G3 exhibited both
alterations. In subline E5 neither pgp gene overexpression nor topoisomerase II alteration could account for the resistance to DOX
and ETO.
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Tabe II Resistance (bold) andcross-resistance to DOX, VCR or ETO
of selected sublines
Resistance indexes to
Resistant subline DOX VCR ETO
AA88DOX.A2 8.la 0.9 3
AA8/DOX.A4 10.2 6.2 4
AA88DOX.A5 10.2 5.9 5.4
AA8/DOX.B6 9.7 5.3 6.3
AA8/VCR.B4 5.3 11.3 6
AA8/VCR.B1 6 10.4 8.3 7
AA8/VCR.C13 10.2 7.4 5.4
AA88VCR.C14 1.1 4 .8 1.5
AA8/ETO.A5 1.9 1.0 8.9
AA8/ETO.B1 2.1 0.9 5.1
AA8/ETO.B2 2.0 1.2 7.5
' PPvaluesforcomparison ofthemean D10 subline and D10 AA8were
0.0012 - 0.032(significant differences) whenRIswereequal orabove 1.9
and 0.084-0.46 (not significant differences) whenRIs were between 0.9
and 1.5.
4). Compared with the parental cells, the relative intensities
of the DNA fragments were similar inall but one subline.
Interestingly, the pattern of the 13th subline (AA8/
DOX + VCR.B3) was similar to that of the DOX-selected
cells AA8/DOX.A6 and B6: pgp2 fragments were the most
intense and the pgp3 gene was less amplified than the pgpl
gene. Subline AA8/DOX + VCR.B3 also had the highest
level of pgp mRNA overexpression among the doubly resis-
tant cells. In spite of the higher selective drug concentration,
the resistance to DOX of the DOX plus VCR-selected cells
was similar to that obtained with the DOX-selected sublines.
In contrast, possibly because of the lack of specificpgpl gene
amplification, RI values to VCR followed the selective drug
concentration: values obtained with a lower selective drug
concentration in the doubly resistant sublines were lower
than that observed with the VCR-selected cells. mRNA
overexpression and pgp gene amplification are potentially
sufficient to evade DOX plus VCR treatment, but topoiso-
merase H modification could also induce resistance to DOX.
Three sublines (AA8/DOX + VCR.B3, Cl and Dl) were
tested for their ability to form cleavable complexes, but all
extracts had the same ability as the AA8 parental extract to
induce cleavable complex formation.
Taken together, these results suggest that, rather than
DNA topoisomeraseII alteration, increased pgp gene copy
number and mRNA overexpresssion account for the double
resistance to VCR and DOX.
Characterisation of the VCR plus ETO-resistant sublines
All but one of the 12 sublines which resisted thecombination
of ETO plus VCR had a reduced ability (up to 30%) to form
cleavable complexes (Figure 5). These 12 sublines also
exhibited pgp gene amplification as well as pgp mRNA
overexpression. No subline presented a specific pgpl
amplification pattern. Compared with the parental cells, the
relative intensities of the DNA fragments were similar in
seven sublines (AA8/ETO +VCR.A3, B2, B3, C3, C6, F2
and G2). The five other sublines (AA8/ETO + VCR.A6, Bl,
B4, E3 and F3) exhibited a pattern similar to that of AA8/
DOX +VCR.B3, AA8/DOX.A6 and B6 cells (i.e. the pgp2
gene was more amplified than the pgpl gene, itself more
amplified than the pgp3 gene). As for AA8/DOX + VCR
cells, RI values obtained with VCR were lower (mean value
of 6) than for the cells selected with VCR only (mean value
of 11.6).
Therefore, two, independent mechanisms of resistance
seem to be required to ensure survival to a combination of
ETO and VCR.
Characterisation ofthe DOXplus ETO-resistant sublines
All combinations of resistance mechanisms were found
within the 18 DOX plus ETO-selected sublines (Figure 6).
Amplification of the pgp genes ranged from very high to
non-detectable and ability to form cleavable complexes
ranged from 10% to indistinguishable from that of the
parental cells. Five sublines exhibited only a decreased ability
to form cleavable complexes (AA8fDOX + ETO.A3, C5, D2,
GI and G4), six displayed pgp mRNA overexpression only
(AA8/DOX + ETO.A5, C3, D5, E4, G5 and H6), whereas
both mechanisms were present in sublines AA8/DOX +
ETO.A2, A4, Bl, B4, C6 and G3. In one sublime (AA8/
DOX + ETO.E5), neither pgp gene amplification nor decreas-
ed ability to form cleavable complexes could account for the
resistance. As for most of the DOX-selected sublines, and for
all but one of the DOX plus VCR-selected sublines, when
pgp gene amplification was observed the relative intensities of
the EcoRI fragments were similar to that of the AA8 paren-
tal cells. Various levels of pgp mRNA expression were
observed, but, as previously, nocorrelation between pgp gene
amplification and mRNA expression could be drawn. Most
high RI values to ETO were among thecells presenting a
decreased ability to form cleavable complexes, but a 30%
decrease in the ability to stabilise cleavable complexes was
associated with both the greatest RI value to ETO (25 in
subline AA8/DOX + ETO.G4), and the RI value of 11 in
subline AA8/DOX + ETO.A3. Furthermore, subline AA8/
DOX + ETO.H6, with pgp amplification only, had a RI
value to ETO of 24.
Our results suggest that either of the two mechanisms, pgp
mRNA overexpression or decreased ability to form the
cleavable complexes, can induce resistance to DOX plus
ETO.
Disaussion
In this study, we verify that DOX, VCR and ETO preferen-
tially select one mechanism of resistancein CHO-AA8 cells,
and we investigate whether there is common or independent
mechanisms of resistance to combinations of these anti-
tumoral drugs. We show that DOX and VCR preferentially
select amplification of the pgp gene-associated multidrug
resistance, whereas ETO resistance results primarily from
topoisomeraseII alteration. We unveil common resistance
mechanisms to combination of these drugs, except for the
VCR plus ETO association, whichrequires selection of two
independent mechanisms.
Clinically used concentrations of antitumoral drugsinduce
emergence of resistant cells. We observed, however, that a
low selective pressure results in a moderate level of resistance
in CHO-AA8 sublines. The alterations conferring resistance
to the antitumoral agents could not result from a mutagenic
response owing to a long exposure to drug or from pretreat-
ment with a mutagen (Singh and Gupta, 1983). Therefore, it
islikely that the selection resulted from a threshold effect:
there were pre-existing mutants which emerged from the
parental population. Consistent with our observations, a low
concentration of vinblastine or colchicine with human
melanoma cells (Lemontt et al., 1988), or of DOX with
murine erythroleukaemia cells (Slapak et al., 1990) also
induce low levels of resistance.
Overexpression of the pgp genes occurred in most CHO-
AA8 sublines selected with VCR or DOX; only one of the
DOX-resistant sublines exhibited a modified ability to form
cleavable complexes. Typically, cells selected with DOX (or
VCR) and featuring pgp gene amplification were cross-
resistant to ETO and VCR (or DOX). The ETO-selected cells
exhibited primarily a modified drug-stimulated ability to
stabilise cleavable complexes; this includes the only sublime
which slightly overexpressed pgp mRNA. Cells selected with
ETO (or DOX) and featuring topoisomerase II alteration
were cross-resistant to DOX (or ETO), but retained their
sensitivity to VCR. Consistent with our data, VCR selects for
pgp overexpression, and ETO selects for topoisomerase II
alteration, whereas both mechanisms of resistance may apply
with DOX. The three drugs are potentially recogmsed by
PGP, but only ETO and DOX can stabilise the complexesDoWW du .dIe
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between DNA and topoisomerase II (Liu, 1989; Georges et
al., 1990; Corbett et al., 1993; Gottesman and Pastan, 1993).
Alterations of topoisomerase II, without overxpresson of
PGP, have been observed in P388 murine leukaemia cells and
human small-cell lung carcinoma cells selcted with DOX
(De Jong et al., 1990; McPherson et al., 1993). In addition,
very few cell lines exhibited the clasical MDR phenotype
after selecion with ETO or teniposide (Long et al., 1991;
Hosking et al., 1994). There was no correlation between pgp
gene amplbition or mRNA overexpression and kevel of
resistance. Regulation of the transcription and/or mRNA
stabilisation may control PGP expression. Overexpression of
PGP without increase in pgp mRNA has been observed in
tumour cells resistant to inca alkaloids (Bradley et al., 1989;
Hill et al., 1990; Biedler, 1994). Resistance to VCR could
result from tubulin alteration (Houghton et al., 1985; Sirot-
nak et al., 1986; Pain et al., 1988). Such a mechanism pos-
sibly accounts for two of the VCR-resastant subines
exhibiting only a slight increase in pgp mRNA. Alternatively,
point mutations in PGP could affect the transporter affinity
for a particular drug (Gottesman and Pastan, 1993). Fmally,
specific drug immunity may be associated with a particular
pgp gene (Georges et al., 1990; Gottesman and Pastan, 1993).
Three patterns ofpgp gene amplifiction were established in
the CHO-AA8 cells. The most common patten was a general
amplification of all three pgpl, pgp2 and pgp3 genes. A
specific pgpl amplfication pattern was found in the VCR-
selected cells, and a preferential amplification of pgp2 gene
characterised some of the DOX-selected cells. In sublines
displaying a general amplfication pattern, the Rls to DOX
were higher than those to VCR, and the resistance to ETO
the lowest. In sublines with specific pgpl amplifiation, the
highs Rls were to VCR, and a relationship seemed to link
the extent of pgpl amplification to the level of VCR resis-
tance. Similarly, a preferred pgp2 amplification may improve
the resistance to DOX. We did not find a specific pgp3 gene
amplification, but transfection of the human mdr3 gene
(homologous to the hamster pgp3 gene) failed to induce the
MDR phenotype in RBO melanoma cells (Gottesman and
Pastan, 1993). While DOX and ETO are both topoisomerase
H poisons, they appear to seect preferentially different
mechanisms of resistance. Topoisomerase H modifications
obtained through DOX selection were far less frequent than
those emerging through ETO selection. Actually, the unique
DOX-selected subline exhibiting topoisomerase H alteration
was only 3-fold cross-resistant to ETO. Conversely, the ETO-
selected sublines which exhibited an impaired ability to form
cleavabk complexes were at most 2-fold cross-resistant to
DOX. However, the DOX- (or VCR) resistant sublines
(overexpressing the pgp genes) were cross-resistant to ETO,
suggesting that pgp gene overexpression may have been
sufficient to confer ETO resistance. Again, independently
from the pgp gene amplification pattern, cross-resisn ce to
ETO was lower than resistance to DOX (or VCR). Consis-
tent with our data, PGP does not recognise ETO as
efficiently as DOX (Politi et al., 1990; Long et al., 1991).
Wbile Giaccone et al. (1992) found a direct relationship
between sensitivity to topoisomerase II poisons and expres-
sion of topoisomerase H, the sensitivity to ETO or teniposide
does not always correlate with reduction in topoisomerase H
level and/or activity (Danks et al., 1988; Ferguson et al.,
1988; Matsuo et al., 1990; Ritke et al., 1994). In our study,
cleavable complex formation was not directly related to the
level of the drug resistance. It has been suggested that 0.35 M
sodium chloride may not fully extract the topoisomerase II.
Nevertheless, different mutations in topoisomerase HI, which
would induce vanous sensitivity to the seecting drug, may
also reconcile these observations (Bugg etal., 1991; Danks et
al., 1993). Cleavable complex formation accounts for both
qualitative and quantitative modifications of either topoiso-
merase H isoform E or 0(Drake etal., 1989; Van der Zee et
al., 1994). In addition, other cellular alterations may confer
resistance to ETO. Two of the ETO-selected sublines
exhibited neither pgp RNA overexpression nor reduced drug-
stimulated DNA cleavage. Possible alternative mechanisms of
reistance include overexpon of another multidrug trans-
porter associated with the MDR phenotype (Grant et at.,
1994; Schneider et al., 1994), inducibl P450 dependent drug-
metabolsing activity (Sinha et al., 1988) and alteration of an
enzyme involved in the glutathione metabolism (Sinha and
Myers, 1984; Haim et al., 1987).
With all the DOX plus VCR-resistant sublines, there was a
common mechanism ofresistance, which corresponded to the
one preferentiallyseted by each drug alone. Simultaneous
resstance to both drugs may have resulted from overexpres-
sion of a singe PGP (which would recognise both drugs).
Alternively, concurrent amp tion of disct pgp genes,
coding for different PGP, may account for the double drug
resistance (Ng et al., 1989; Gottesman and Pastan, 1993).
While the general pgp gene amplification observed supports
the latter hypothesis, both are in agreement with the high
frequency ofcells surviving DOX plus VCR treatment, which
is similar to the frequency resulting from selection with DOX
or VCR alone (Soues and Charcosset, 1993). In contrast, the
frequency observed with the ETO plus VCR-slected cells
was rather low, suggesting that two mutational events may
be necesary to ensure simultaneous resistance (Soues and
Charcosset, 1993). lndeed, we observed, in all but one of the
ETO plus VCR-seleted sublines, both pgp mRNA overex-
pression and decreased ability to form cleavable complexes.
While cells seleted with ETO retained sensitivity to VCR,
cells selce with VCR alone were cross-reistant to ETO.
Two mechanisms of resistance were selected, yet resistance to
VCR alone alleviated the sensitivity to ETO. It is conceivable
that the relatively low cross-reistance to ETO in cells
selcted with VCR alone rationalises tis apparent contradic-
tion: the need for a higher resistance to ETO would exdude
PGP as a major source of protection in the doubly selcted
sublines. With the DOX plus ETO-seected cells, either one
or both mechanisms were observed. Here, each mechanism
could account for the double resistance: pgp overexpression
(preferentially sekcted by DOX) procured cross-resistance to
ETO and topoisomerase H alteration (almost systematically
selected by ETO) ascertained the resistance of one of the
DOX-selcted sublines. PGP overexpresson seemed, how-
ever, to be required for high DOX resiance, and
topoisomerase II modification was associated with high resis-
tance to ETO. This observation is compatible with the low
cross-reistance to DOX of the ETO-sekcted sublines and
with the moderate cross-resistance to ETO of the DOX-
resistant cells. DOX plus ETO combination selected a
heterogeneous population with either or both common
mechanisms. The selection of single and double mutants
probably accounted for the intermediate frequency of resis-
tant cells observed: higher than the product of single resis-
tance frequencies (as with the VCR plus ETO-resistant cells),
but lower than either of the single resistance frequencies, as
with the VCR plus DOX-seect cells (Soues and Char-
cosset, 1993). Fmally, in one of the ETO plus DOX-resistant
sublines, neither pgp overexpression nor topoisomerase H
alteration was d d. In addition, a high resistance to ETO
was observed in some ofthe doubly resistant sublines, despite
an unchanged ability to form cleavable complexes. While an
increased level of PGP without mRNA overexpresson can-
not be ruled out (Bradley etal., 1989; Hill et al., 1990), other
modifications, as above, may have conferred resitance to
ETO (Sinha and Myers, 1984; Haim et al., 1987; Sinha et al.,
1988; Schneider et al., 1994) and DOX (Sinha and Chigneli,
1979; Berlin and Haseltine, 1981; Zaman et al., 1993; Bar-
rand et al., 1994). Resistance to both drugs could also result
from alteration in the lethal processing of the cleavable com-
plexes (Schneider et al., 1990; Glisson et al., 1992).
Abbrevitom PGP, P-glycoprotein; MDR, multidrug resistance;
mdr, MDR-associated genes;pgp, MDR-associated genes in hamster
species; VCR, vincristine; ETO, etoposide; DOX,doxorubicin (Adri-
blastine); RI, resistance index; D1O, 10% survival dose; CAD, poly-
peptide having carbaymyl phosphate synthetase, aspartate transcar-
bamylase and dihydroorotase activities.Doube dg k sstce
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